Patient P-03239
Therapy response
Improving
Tolerance
Deteriorating
GI state
Favorable
Inflammatory state
Favorable
Nutritional resilience
Declining
Discontinuation risk
10%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S18
- Day 28 HY-01 recommended — Hydration Protocol HY-01
- Day 29 Patient accepted — Started HY-01 in the companion
- Day 33 No meaningful change — Hydration Protocol HY-01
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- Nutritional resilience-12
- Toxicity+12
- Treatment adherence-2
What helped?
- Hydration Protocol HY-01Day 28Result: no meaningful change
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Energy level
Daily log7.1/10
worsening · -0.5 vs previous 14 d
Stress level
Daily log3.6/10
worsening · +0.5 vs previous 14 d
Pessimism score
Daily log2.4/10
stable · +0.0 vs previous 14 d
Sleep quality
Wearable70.6/100
worsening · -4.5 vs previous 14 d
Libido
Daily log5.4/10
worsening · -0.6 vs previous 14 d
HRV
Wearable59 ms
worsening · -4.1 vs previous 14 d
Toxicity
Blood21/100
worsening · +1.5 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards restoration · 92 from the failing basin, 6 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More proteinGI -4.9 next day on high-intake days · n 15
Would not help
- HY-01 Hydration Protocolalready tried, no meaningful change
- Keep lactose lowGI +4.5 next day on high-intake days · n 18
- Keep alcohol lowGI +4 next day on high-intake days · n 19
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-4.9supporter · 95%
- Lactose+4.5detractor · 95%
- Alcohol+4detractor · 95%
- Dietary fat load+1no signal · 22%
- Caffeine-0.7no signal · 16%
- Histamine load+0.3no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↑45
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- Mucosal barrier integrity ↓30
- MicrobiomeAkkermansia low → thinner mucus layer
- Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Intermediate metabolizerExpected exposure
Microbiome
Shannon diversity 4.4 · butyrate capacity 45/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 56 ms
- Sleep
- 8.1 h
- Steps
- 3,754
- Resting HR
- 59 bpm
Daily log: GI score 13, nutritional resilience 62, adherence 95.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.